Patient Support Services Contact Us



Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News
REDWOOD CITY, Calif. , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will be presenting at the 27th Annual Credit Suisse Healthcare Conference being held in Scottsdale, Arizona on Thursday, November 15 at 9:45 am MST .
REDWOOD CITY, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended September 30 , 2018.   Third Quarter 2018 and Recent Corporate Highlights Include:               On September
REDWOOD CITY, Calif. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration ( FDA ) has approved UDENYCA™ (pegfilgrastim-cbqv), the first pegfilgrastim biosimilar approved by both the FDA and the European Commission
REDWOOD CITY, Calif. , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced that its third quarter 2018 financial results will be released after market close on Thursday, November 8 , 2018.  Starting at 4:30 p.m. ET , Coherus’ management will host a conference
Upcoming Events
There are currently no events scheduled.

Receive E-mail Alerts

Click here to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site.


Copyright West LLC. Minimum 15 minutes delayed.